Fiber Control in Sterile Injectables: Preventing Particulate Recalls

Every particulate matter recall traces back to the same question, and it's one I ask on every injectable-manufacturing audit I run: what was allowed into the room that shouldn't have been there? Not what went wrong in the abstract — what specific material, in what specific location, touched the product or its container before the defect was caught. That question is more useful than any headline about a recalled lot number, because the answer is almost always a controllable one.

On July 24, 2026, Baxter International announced a voluntary nationwide recall of one lot of Cefazolin in Dextrose Injection, USP, 2g/100mL (20mg/mL), single-dose containers — Lot LD175708, expiring February 14, 2027 — after a customer reported particulate matter in the solution that was identified as cardboard. I'm not going to spend this article narrating that event. Baxter's public notice and FDA's recall posting cover the facts. What I want to walk through is the part that matters more to every other sterile manufacturer reading this: which specific GMP controls, applied consistently, keep fiber and paper-based contamination out of an injectable solution in the first place — and where those controls tend to break down in real facilities.

Why Cardboard Shows Up in Injectable Solutions

Corrugated fiberboard is everywhere in a pharmaceutical plant. It arrives on shipping pallets, wraps component trays, forms the outer cartons that vials and IV bags ship in, and gets used as makeshift dunnage on the production floor more often than any quality manual admits. It also sheds. Cellulose fibers release from corrugated board with ordinary handling — cutting, stacking, taping, even just moving a box across a room creates airborne fiber and dust. In an ISO-classified cleanroom, that shedding is a direct threat to an open fill line, because a single fiber falling into an uncapped container is a foreign-particulate event, not a hypothetical one.

This is precisely why global GMP guidance draws such a hard line on paper and fiberboard inside classified space. The revised EU GMP Annex 1 (effective August 25, 2023) states plainly that materials which generate particles, such as cardboard, wood, or other fiber-shedding materials, should not enter the grade B, A, or equivalent cleanroom areas. FDA's own 2004 Guidance for Industry on Sterile Drug Products Produced by Aseptic Processing makes the same point in different language, calling out packaging and shipping materials as a recognized contamination vector that facilities must control through material airlocks, de-boxing procedures, and gowning discipline before anything crosses into the aseptic core. A cardboard particle recovered from a finished dose almost never originates at the point of detection — it's a trace of a control that failed somewhere upstream, usually at a material transfer step nobody was watching closely.

The Regulatory Framework: 21 CFR 211 and the USP Particulate Chapters

U.S. manufacturers of parenteral products operate under a specific overlapping set of requirements, and I'd encourage any quality leader reading this to pull these citations up and check them against their own site's procedures this week, not next quarter.

21 CFR 211.72 is the most directly on-point regulation for this exact contamination type. It states that filters used in the manufacture, processing, or packing of injectable drug products shall not release fibers into the product, and that fiber-releasing filters may not be used unless it is not possible to manufacture the product without them — and even then, an additional non-fiber-releasing filter must follow. This regulation exists because the agency has seen fiber contamination in injectables often enough to write a standalone rule about it.

21 CFR 211.65(a) requires that equipment used in manufacturing not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality, or purity of the drug product beyond specification. Fixtures, trays, and work surfaces that shed particulate fall under this same umbrella even when they aren't classified as "equipment" in the traditional sense.

21 CFR 211.84 governs the testing and approval of components, drug product containers, and closures — including the paperboard cartons and corrugated shippers that hold sterile components before they enter the fill suite. A site that never tests or qualifies its incoming packaging materials for particulate-shedding risk has a gap at exactly the point where this recall's contamination most likely originated.

21 CFR 211.113(b) requires written procedures for aseptic processing designed to prevent microbiological and, by extension, particulate contamination of drug products purporting to be sterile — and 211.94 requires that containers and closures provide adequate protection against contamination.

On the compendial side, USP General Chapter <788>, Particulate Matter in Injections, sets the actual acceptance limits. For small-volume injections of 100 mL or less, Method 1 (light obscuration) limits finished product to no more than 6,000 particles per container at 10 microns or larger and no more than 600 particles per container at 25 microns or larger. USP <1>, Injections and Implanted Drug Products, requires that every unit be essentially free from visible particulates as part of release testing, and USP <790>, Visible Particulates in Injections, gives manufacturers the actual visual inspection methodology — light intensity, background, viewing distance, and inspector qualification — that turns "essentially free from particulates" into a repeatable test rather than a judgment call. A cardboard fiber large enough for a customer to observe with the naked eye, as reported in this recall, should have been visible to a properly trained inspector under <790> conditions well before the product left the plant.

Manufacturing Controls That Actually Prevent This

Regulations tell you what to achieve. They don't tell you how to run a fill line. In my experience walking sterile manufacturing floors, the facilities that don't have particulate events share a specific set of physical and procedural habits, and the ones that do have events are almost always missing one of these:

Material airlocks with mandatory de-boxing. Every component, tray, and consumable gets stripped of its corrugated outer packaging in a dedicated airlock before it crosses into any classified space. No exceptions for "it's just going to the gowning room" or "it's only staged there for an hour." A cardboard box staged next to an open fill line for a shift changeover is a contamination event waiting for a witness.

Depalletizing and wipe-down procedures with documented verification. Components arriving on wood pallets or in fiberboard cases get wiped down with a lint-free, non-shedding material and transferred to cleanroom-compatible totes — stainless, polypropylene, or similarly non-shedding plastic — before entering controlled space. This step needs a signature in the batch record, not just a line in an SOP nobody references.

Environmental monitoring data reviewed for trend, not just pass/fail. Particle counts and settle plates that are individually "within limits" but trending upward over several batches are an early warning that something — a gowning lapse, a failed HEPA filter, a new packaging vendor's material — has changed. A quality system that only checks whether today's number crossed the action limit misses the signal that would have caught this weeks earlier.

100% visual inspection under USP <790> conditions, with inspector qualification renewed on a fixed schedule. Automated inspection systems catch a great deal, but manual inspection under the specified lighting and background conditions remains the backstop for irregular foreign material like a fiber or paper fragment, which doesn't always present the way a glass lamination flake or rubber coring particle does. If your inspectors haven't been re-qualified against a defect reference set in the last twelve months, that's a finding waiting to happen.

Supplier and component change control that flags packaging material changes as GMP-relevant. A shipper carton switching corrugate grades or a new tray vendor is not a purchasing decision — it's a change that touches product contact risk and belongs in your change control system with quality sign-off, not just a procurement email chain.

I've come to think the single biggest predictor of a particulate recall isn't the fill line technology or the cleanroom classification on paper — it's whether a site treats packaging material handling as a quality-owned process or a warehouse-owned one. When packaging sits organizationally under logistics with no quality touchpoint, fiber contamination risk goes up regardless of how good the actual filling equipment is.

What This Recall Means for Your Recall Readiness, Too

Baxter's recall was voluntary and nationwide, initiated after a single customer complaint identified the particulate as cardboard — which tells you something important about their complaint-handling system: it worked. A single report triggered lot investigation, root cause work, and action fast enough to reach a public notice within what appears to be a short window of the initial report. That's the other half of this lesson. Prevention controls reduce how often these events happen. A responsive complaint and CAPA system determines how fast you catch the ones that get through anyway.

Under FDA's recall regulations at 21 CFR Part 7, Subpart C, once a firm classifies and initiates a recall, it must notify direct accounts promptly and follow up with written notification, and FDA reviews the firm's recall strategy for effectiveness — including whether the depth of recall (consumer level, retail level, or wholesale level) matches the health risk. Single-dose IV admixture products, distributed largely through hospital pharmacy and wholesale channels rather than direct-to-consumer retail, typically recall at the user/wholesale level, which is faster to execute and easier to verify complete than a consumer-level recall would be. If your facility manufactures injectables and hasn't run a mock recall exercise in the last twelve months to confirm you can trace a lot to its distribution endpoints within a matter of hours, that's a gap worth closing before you need the capability under real pressure.

A Compliance Checklist Worth Running This Month

• Confirm your material airlock and de-boxing SOP names every packaging material type entering classified space, not a generic reference to "components."
• Pull the last six months of environmental monitoring trend data and look for slow upward drift, not just excursions.
• Verify USP <790> inspector qualification records are current and tied to a defect reference set that includes fiber and paper particulate examples.
• Check whether packaging material or component vendor changes in the last year went through formal change control with quality approval.
• Run a mock recall from lot number to distribution endpoint and time how long it takes; FDA expects firms to execute recall strategies without delay once initiated.
• Review your 21 CFR 211.72 filter validation documentation to confirm it addresses fiber release testing specifically, not just bioburden reduction.

FAQ

What causes cardboard or fiber contamination in injectable drug products? Corrugated fiberboard and paper-based packaging shed cellulose fibers during normal handling — cutting, stacking, and moving. When these materials enter a classified cleanroom or sit near an open fill line, fibers can settle into open containers before sealing, which is why GMP guidance restricts fiberboard from aseptic core areas entirely.

Which FDA regulation specifically addresses fiber contamination in injectables? 21 CFR 211.72 directly addresses this, prohibiting filters that release fibers into injectable drug products and restricting the use of fiber-releasing filters unless a subsequent non-fiber-releasing filter is also used.

What particulate matter limits apply to small-volume injectable products? USP General Chapter <788>, using Method 1 light obscuration testing, limits small-volume injections of 100 mL or less to no more than 6,000 particles per container at 10 microns or larger and no more than 600 particles per container at 25 microns or larger.

Is a recall for visible particulate matter always high risk? Risk depends on the specific particulate's composition, size, and the administration route. Particulates entering the bloodstream via IV administration carry risk of local irritation, phlebitis, or, for larger or more numerous particles, embolic events — which is why even a single credible complaint typically triggers immediate lot investigation and recall action.

How often should sterile manufacturing sites requalify visual inspectors? There's no single universal interval mandated by USP <790>, but annual requalification against a documented defect reference set — including foreign material types like fiber, glass, and rubber particulate — is standard industry practice and something FDA investigators routinely ask to see evidence of during pre-approval and routine GMP inspections.

If your site handles sterile fill-finish operations and you want a second set of eyes on your packaging material controls, environmental monitoring trend analysis, or visual inspection program before an investigator or a customer complaint finds the gap first, that's exactly the kind of assessment my team runs for clients through Certify Consulting's GMP quality systems services. I also work with manufacturers on contamination control strategy development specifically because Annex 1's 2023 requirements have made this a documented, standalone deliverable rather than an implicit assumption baked into your cleanroom design.

Last updated: 2026-07-30